title: Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.
abstract: The new ACC/AHA guidelines on treatment of blood cholesterol focus on intensity of statin therapy rather than target levels of lipids. Early studies show substantial reductions in LDL-cholesterol level with antibodies against PCSK9. MicroRNA silencing and gene-repair techniques to treat dyslipidaemia are promising strategies under development.
authors.affiliation: Department of Clinical Biochemistry (Vascular Prevention Clinic), Royal Free Hospital Campus, University College School of Medicine, Pond Street, London NW3 2QG, UK.
authors.forename: Dimitri P
authors.initials: DP
authors.lastname: Mikhailidis
authors.affiliation: Atherosclerosis and Metabolic Syndrome Outpatient Units, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 15 Marmara Street, 55132 Thessaloniki, Greece.
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
mesh_terms: D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids